China Universal Asset Management Co. Ltd. Increases Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

China Universal Asset Management Co. Ltd. raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 68.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,466 shares of the company's stock after buying an additional 8,685 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in Vaxcyte were worth $2,453,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Principal Financial Group Inc. raised its stake in Vaxcyte by 11.8% in the 1st quarter. Principal Financial Group Inc. now owns 24,597 shares of the company's stock worth $1,680,000 after acquiring an additional 2,589 shares during the last quarter. Capstone Investment Advisors LLC acquired a new stake in shares of Vaxcyte during the first quarter worth about $7,472,000. Fidelis Capital Partners LLC purchased a new stake in Vaxcyte in the first quarter valued at approximately $37,000. SG Americas Securities LLC acquired a new position in Vaxcyte in the 1st quarter worth approximately $298,000. Finally, ClariVest Asset Management LLC acquired a new stake in Vaxcyte during the 1st quarter valued at approximately $283,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Insider Activity at Vaxcyte

In related news, SVP Mikhail Eydelman sold 5,000 shares of the firm's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $109.27, for a total transaction of $546,350.00. Following the completion of the sale, the senior vice president now directly owns 28,623 shares in the company, valued at approximately $3,127,635.21. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Vaxcyte news, SVP Mikhail Eydelman sold 5,000 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $109.27, for a total value of $546,350.00. Following the transaction, the senior vice president now owns 28,623 shares of the company's stock, valued at $3,127,635.21. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the sale, the chief executive officer now owns 478,888 shares of the company's stock, valued at approximately $37,822,574.24. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 92,098 shares of company stock valued at $9,937,773. 3.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on PCVX shares. Jefferies Financial Group raised their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. BTIG Research lifted their price target on Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Mizuho boosted their price target on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a report on Tuesday, September 10th. Bank of America boosted their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Finally, Leerink Partners raised their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a research report on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte presently has a consensus rating of "Buy" and a consensus target price of $147.50.

Vaxcyte Stock Down 6.4 %

Shares of NASDAQ PCVX traded down $7.24 during trading on Tuesday, hitting $105.56. The company had a trading volume of 1,777,946 shares, compared to its average volume of 832,770. Vaxcyte, Inc. has a fifty-two week low of $46.16 and a fifty-two week high of $121.06. The stock has a fifty day simple moving average of $106.76 and a two-hundred day simple moving average of $84.80. The firm has a market capitalization of $11.78 billion, a price-to-earnings ratio of -22.46 and a beta of 0.99.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, topping analysts' consensus estimates of ($1.14) by $0.04. During the same quarter last year, the business earned ($0.70) EPS. On average, analysts anticipate that Vaxcyte, Inc. will post -4.33 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.